Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

• Thomas Powles,
• Toni K. Choueiri,
• Robert J. Motzer,
• Eric Jonasch,
• Sumanta Pal,
• Nizar M. Tannir,
• Sabina Signoretti,
• Rajesh Kaldate,
• Christian Scheffold,
• Evelyn Wang,
• Dana T. Aftab,
• Bernard Escudier,
• Daniel J. George

Affiliations

Thomas Powles

Barts Cancer Institute, Queen Mary University of London

Toni K. Choueiri

Dana-Farber Cancer Center

Robert J. Motzer

Memorial Sloan Kettering Cancer Center

Eric Jonasch

University of Texas MD Anderson Cancer Center

Sumanta Pal

City of Hope National Medical Center

Nizar M. Tannir

University of Texas MD Anderson Cancer Center

Sabina Signoretti

Brigham and Women’s Hospital

Rajesh Kaldate

Exelixis, Inc

Christian Scheffold

Exelixis, Inc

Evelyn Wang

Exelixis, Inc

Dana T. Aftab

Exelixis, Inc

Bernard Escudier

Gustave-Roussy

Daniel J. George

Duke Cancer Institute